Novartis Reports Positive Phase III Results for Next-Generation Malaria Drug GanLum
Novartis AG has reported positive Phase III results for its next-generation malaria drug, GanLum (KLU156), developed with Medicines for Malaria Venture. The KALUMA study showed GanLum's cure rate at 97.4%, surpassing the 94.0% rate of the current standard treatment, artemether-lumefantrine. With plans to seek regulatory approvals, GanLum could be the first major innovation in malaria treatment in over 25 years. The results were officially announced by Novartis.
Novartis AG has announced positive results from the Phase III KALUMA study evaluating KLU156 (ganaplacide/lumefantrine, or GanLum), a novel non-artemisinin antimalarial treatment developed in collaboration with Medicines for Malaria Venture (MMV). The study met its primary endpoint, demonstrating non-inferiority to the current standard of care, artemether-lumefantrine (Coartem®). GanLum achieved a 97.4% PCR-corrected cure rate using an estimand framework, compared to 94.0% for the standard of care. Conventional per protocol analysis showed cure rates of 99.2% and 96.7%, respectively. Novartis plans to seek regulatory approvals for GanLum, which could represent the first major innovation in malaria treatment since artemisinin-based combination therapies were introduced over 25 years ago. The results have already been announced by Novartis. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novartis AG published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001138205-en) on November 12, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
